Abstract: Stable pharmaceutical formulations for therapeutic anti-IL-23p19 antibodies and methods of using such stable pharmaceutical formulations.
| # | Name | Date |
|---|---|---|
| 1 | 202317025405-STATEMENT OF UNDERTAKING (FORM 3) [04-04-2023(online)].pdf | 2023-04-04 |
| 2 | 202317025405-Sequence Listing in txt [04-04-2023(online)].txt | 2023-04-04 |
| 3 | 202317025405-Sequence Listing in PDF [04-04-2023(online)].pdf | 2023-04-04 |
| 4 | 202317025405-REQUEST FOR EXAMINATION (FORM-18) [04-04-2023(online)].pdf | 2023-04-04 |
| 5 | 202317025405-POWER OF AUTHORITY [04-04-2023(online)].pdf | 2023-04-04 |
| 6 | 202317025405-FORM-26 [04-04-2023(online)].pdf | 2023-04-04 |
| 7 | 202317025405-FORM 18 [04-04-2023(online)].pdf | 2023-04-04 |
| 8 | 202317025405-FORM 1 [04-04-2023(online)].pdf | 2023-04-04 |
| 9 | 202317025405-DRAWINGS [04-04-2023(online)].pdf | 2023-04-04 |
| 10 | 202317025405-DECLARATION OF INVENTORSHIP (FORM 5) [04-04-2023(online)].pdf | 2023-04-04 |
| 11 | 202317025405-COMPLETE SPECIFICATION [04-04-2023(online)].pdf | 2023-04-04 |
| 12 | 202317025405.pdf | 2023-04-08 |
| 13 | 202317025405-FORM 3 [10-04-2023(online)].pdf | 2023-04-10 |
| 14 | 202317025405-RELEVANT DOCUMENTS [19-04-2023(online)].pdf | 2023-04-19 |
| 15 | 202317025405-MARKED COPIES OF AMENDEMENTS [19-04-2023(online)].pdf | 2023-04-19 |
| 16 | 202317025405-FORM 13 [19-04-2023(online)].pdf | 2023-04-19 |
| 17 | 202317025405-AMMENDED DOCUMENTS [19-04-2023(online)].pdf | 2023-04-19 |
| 18 | 202317025405-Proof of Right [18-08-2023(online)].pdf | 2023-08-18 |